The IPO is a fresh issuance aggregating to Rs 500 crore and an offer for sale of face value of Rs 2 each by the promoter selling shareholde...

This will be the largest IPO by a pharmaceutical company in India. The biggest IPO till date in the sector was from Eris Lifesciences, whic...

The firm is India’s largest manufacturer of specialised chemicals, such as Hexamethyldisilazane / Hexamethyldisilane (HMDS) and Chloromethy...

The IPO appears to be richly valued when compared with listed peers.

HDFC Securities in a note said it met with the management of some emerging formulations players such as Granules India and Laurus Labs.

The company repaid long term loans of Rs 226.3 crore from the proceeds of Rs 1,332 crore raised through an initial public offering (IPO) in...

The drugmaker sold its Rs 1,332 crore initial public offering (IPO) between December 6 and December 8, which was subscribed 4.52 times.

Kotak Mahindra Capital Company, Citigroup Global Markets India, Jefferies India and SBI Capital Markets were the book running lead managers...

The quota limit for qualified institutional buyers (QIB) category was subscribed 10.54 times, the retail individual investor (RII) category...

The company intends to utilise the proceeds from the sale of fresh shares in the IPO to pre-pay term loans and for other general corporate ...

The issue received bids for 62,09,420 shares as against 2,19,11,308 on offer, data available with the stock exchanges till 5 pm showed.

As on 30th September, we have at debt of about 1100 crore and then we already repaid about 140 crore, so current debt is about 960 and out ...

The company is raising Rs 1,330 crore in the primary market. Proceeds of Rs 225 crore from the issue will be used to reduce debt on the com...

Brokerage ICICI Securities believe at the upper end of the price band the stock is fairly priced, after considering the growth prospects, p...

The Hyderabad-based company plans to utilise the net proceeds from the fresh issue towards pre-payment of term loans and general corporate ...

The issue consists of an offer for sale (OFS) of 24,107,440 equity shares by existing shareholders Aptuit, Bluewater, FIL Capital Managemen...

The company is expected to dilute up to 25% stake in the share sale, which will value the company at about Rs 4,000 crore, they said.